{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(3)"],"submitter":["Kang JK"],"pubmed_abstract":["Introduction
The goal of this study was to evaluate the efficacy and safety of high-dose stereotactic body radiation therapy (SBRT) with an extended (48 h or more) interfraction interval for hepatocellular carcinoma (HCC) ≤5 cm in size after incomplete response to transarterial chemoembolization (TACE).Methods
This multicenter prospective study included 54 patients with inoperable HCC of ≤5 cm size between July 2012 and June 2015. A total SBRT dose of 60 Gy in 3 fractions was administered within 14 days with ≥48-h interfraction interval to patients who showed an incomplete response after 1-5 sessions of TACE. Treatment responses were defined according to the modified Response Evaluation Criteria for Solid Tumors. Toxicities were evaluated using the Common Terminology Criter"],"journal":["Liver cancer"],"pagination":["248-259"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12180793"],"repository":["biostudies-literature"],"pubmed_title":["Long-Term Outcome of a Multicenter Prospective Study on Efficacy and Safety of High-Dose Stereotactic Body Radiation Therapy ≥48-h Interfraction Interval for ≤5 cm Hepatocellular Carcinoma."],"pmcid":["PMC12180793"],"pubmed_authors":["Shin YJ","Kim MS","Kang JK","Chang AR","Kim HJ","Kim E","Park HJ","Kim WC","Kim ES","Bae SH","Kim J","Choi CW","Jang WI","Park Y","Han CJ","Park SC","Jeon W","Yu T","Jo S"],"additional_accession":[]},"is_claimable":false,"name":"Long-Term Outcome of a Multicenter Prospective Study on Efficacy and Safety of High-Dose Stereotactic Body Radiation Therapy ≥48-h Interfraction Interval for ≤5 cm Hepatocellular Carcinoma.","description":"Introduction
The goal of this study was to evaluate the efficacy and safety of high-dose stereotactic body radiation therapy (SBRT) with an extended (48 h or more) interfraction interval for hepatocellular carcinoma (HCC) ≤5 cm in size after incomplete response to transarterial chemoembolization (TACE).Methods
This multicenter prospective study included 54 patients with inoperable HCC of ≤5 cm size between July 2012 and June 2015. A total SBRT dose of 60 Gy in 3 fractions was administered within 14 days with ≥48-h interfraction interval to patients who showed an incomplete response after 1-5 sessions of TACE. Treatment responses were defined according to the modified Response Evaluation Criteria for Solid Tumors. Toxicities were evaluated using the Common Terminology Criter","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jun","modification":"2026-06-03T06:54:46.007Z","creation":"2026-04-25T03:21:45.27Z"},"accession":"S-EPMC12180793","cross_references":{"pubmed":["40547960"],"doi":["10.1159/000541685"]}}